Unlike TNBC,8-12 effective interventions for HER2+ tumors adapted to the presence or absence of residual disease exist,38 even if the tumor converts to HER2– after preoperative chemotherapy.39 With a median follow-up of 2.9 years at the time of data cutoff (range, 1.05-4.56) in this subgroup, no death events have occurred. This evidence concerns the gene ERBB2 and neoplasm.